Since May 28th EVERAI Medical Technologies is a new legally constituted start-up. For the last months its team has been working in the development of a software that will facilitate exchanging live-saving patient data between ambulance and hospital physicians. Thanks to this solution the ambulance professionals will be able to share complete, objective structured data with the emergency staff located at the hospital. This will allow the emergency doctor to reduce critical time for the treatment of injured or seriously ill people by already preparing staff and infrastructure before the arrival of the patient. In an emergency situation, saving time can make a difference between life and death.

For now GENESIS Biomed will be the only shareholder of the company. A plan will allow the entry of new key shareholders.

GENESIS Biomed CEO Josep Lluís Falcó sees the creation of the company as “great news in the uncertain times we are living due to the Covid-19 pandemic. EVERAI brings a solution to an unmet need and I am fully confident that it will benefit a great number of patients. It has an enormous potential as data can save lives in a critical moment for a patient.”

EVERAI Medical Technologies was born in 2020 as a project supported by European innovation institute EIT Digital and the involvement of various partners: IMECrenowned Belgian institute focused on nanoelectronics and digital technologies; Pipple, a Dutch company specialised in artificial intelligence; and consultancy firm GENESIS Biomed, responsible for drafting the business plan, generating the IP license agreement and initiating the start-up.

In the coming months GENESIS Biomed will look for financing so the start-up can develop its business plan and hire the necessary staff.

Lowering the administrative burden for medical staff

The EVERAI solution wants to diminish the administrative burden for the medical staff by digitising information that is shared between the ambulance doctor and the hospital emergency doctor. This way the hospital receives validated and structured information about the patient before his/her arrival. Patient data is gathered through an AI voice-to-text solution.

Scientist Astrid Philippron, EVERAI project manager at IMEC explains that “the solution is tailored to specific needs in the market. First we looked at how the end customer was working and what its challenges were. Only thereafter we tried to see how technology may be a solution to that challenge and what specific technology we needed. As we are not bounded to specific technological solutions, the EVERAI product is tailor-made to fit the needs of the end user.“

*Are you interested in EVERAI’s solution? Get in touch with GENESIS Biomed (contact@genesis-biomed.com).

Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream